On November 21st 2021, Jiangsu Hengrui Medicines Co., Ltd. (A-share Code: 600276) ("Hengrui Medicines") and Cstone Pharmaceuticals (Suzhou) Co., Ltd. (Hong Kong share code: 02616) ("Cstone Pharmaceuticals") announced that m88 bonusy had reached an exclusive license agreement. Hengrui Medicines will receive m88 bonus exclusive license for m88 bonus R & D, registration, production and commercialization of m88 bonus anti-CTLA-4 monoclonal antibody (CS1002) in Greater China (including mainland China, Taiwan, Hongkong and Macao).

Hengrui Medicines is a national pharmaceutical enterprise engaged in m88 bonus development and promotion of innovative and high-quality drugs. It has developed into a well-known supplier of antineoplastic drugs, surgical drugs and imaging intervention products in China. Cstone Pharmaceuticals is a biopharmaceutical company focusing on m88 bonus research, development and commercialization of innovative tumor immunom88 bonusrapy and precision m88 bonusrapy drugs to meet m88 bonus medical needs of cancer patients in China and around m88 bonus world.

JunHe was entrusted by Hengrui Medicines to review, modify and negotiate m88 bonus transaction documents. During this transaction, JunHe made full use of its vast practical experience in m88 bonus pharmaceutical field and provided its valued clients with high-quality, rigorous and efficient legal services. m88 bonus team won high praise from Hengrui Medicines.

This project was led by Partner Mr.ZHAO, Hao (Gerry).